19 June 2013
Keywords: ec, approves, novartis, galvus, europe, swiss, drug
Article | 08 October 2007
Swiss drug major Novartis says that its anti-diabetic Galvus (vidagliptin) has been approved by the European Commission. The
dipeptidyl peptidase-4 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 October 2007
© 2013 thepharmaletter.com